What is the current valuation of the Prenatal Diagnostics Market as of 2024?

The Prenatal Diagnostics Market was valued at 9.2 USD Billion in 2024. Read More

What is the projected market size for the Prenatal Diagnostics Market by 2035?

The market is projected to reach 32.32 USD Billion by 2035. Read More

What is the expected CAGR for the Prenatal Diagnostics Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 12.1%. Read More

Which test type segment is anticipated to have the highest growth in the Prenatal Diagnostics Market?

Non-Invasive Prenatal Testing (NIPT) is expected to grow from 3.5 USD Billion to 12.5 USD Billion. Read More

What are the key disease types addressed in the Prenatal Diagnostics Market?

Key disease types include Chromosomal Abnormalities, Neural Tube Defects, and Genetic Disorders. Read More

How does the market for Chromosomal Abnormalities compare to other disease types?

The market for Chromosomal Abnormalities is projected to grow from 2.76 USD Billion to 10.56 USD Billion. Read More

What technologies are driving advancements in the Prenatal Diagnostics Market?

Next-Generation Sequencing (NGS) is projected to expand from 2.5 USD Billion to 9.5 USD Billion. Read More

Who are the leading companies in the Prenatal Diagnostics Market?

Key players include Roche, Abbott, Illumina, and PerkinElmer. Read More

What is the growth potential for Ultrasound in the Prenatal Diagnostics Market?

The Ultrasound segment is expected to grow from 2.0 USD Billion to 7.0 USD Billion. Read More

What role do biochemical markers play in the Prenatal Diagnostics Market?

Biochemical markers are projected to increase from 3.2 USD Billion to 10.0 USD Billion. Read More

Prenatal Diagnostics Market

Prenatal Diagnostics Market Research Report By Test Type (Non-Invasive Prenatal Testing (NIPT), Chorionic Villus Sampling (CVS), Amniocentesis, Ultrasound, Blood Tests), By Disease Type (Chromosomal Abnormalities (e.g., Down Syndrome, Trisomy 18), Neural Tube Defects (e.g., Spina Bifida, Anencephaly), Genetic Disorders (e.g., Cystic Fibrosis, Sickle Cell Disease), Heart Defects, Birth Defects), By Technology (Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Microarrays, Karyotyping, Biochemical Markers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

12.1%

2024 Market Size

$ 9.2 Billion

2035 Market Size

$ 32.32 Billion

Medical Device ● Updated April 2026 Report ID: MRFR/MED/25473-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Test Type (USD Billion) | |
  1. 4.1.1 Non-Invasive Prenatal Testing (NIPT) | |
  2. 4.1.2 Chorionic Villus Sampling (CVS) | |
  3. 4.1.3 Amniocentesis | |
  4. 4.1.4 Ultrasound | |
  5. 4.1.5 Blood Tests |
2. 4.2 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.2.1 Chromosomal Abnormalities (e.g., Down Syndrome, Trisomy 18) | |
  2. 4.2.2 Neural Tube Defects (e.g., Spina Bifida, Anencephaly) | |
  3. 4.2.3 Genetic Disorders (e.g., Cystic Fibrosis, Sickle Cell Disease) | |
  4. 4.2.4 Heart Defects | |
  5. 4.2.5 Birth Defects |
3. 4.3 Healthcare, BY Technology (USD Billion) | |
  1. 4.3.1 Next-Generation Sequencing (NGS) | |
  2. 4.3.2 Fluorescence In Situ Hybridization (FISH) | |
  3. 4.3.3 Microarrays | |
  4. 4.3.4 Karyotyping | |
  5. 4.3.5 Biochemical Markers |
4. 4.4 Healthcare, BY Region (USD Billion) | |
  1. 4.4.1 North America | | |
    1. 4.4.1.1 US | | |
    2. 4.4.1.2 Canada | |
  2. 4.4.2 Europe | | |
    1. 4.4.2.1 Germany | | |
    2. 4.4.2.2 UK | | |
    3. 4.4.2.3 France | | |
    4. 4.4.2.4 Russia | | |
    5. 4.4.2.5 Italy | | |
    6. 4.4.2.6 Spain | | |
    7. 4.4.2.7 Rest of Europe | |
  3. 4.4.3 APAC | | |
    1. 4.4.3.1 China | | |
    2. 4.4.3.2 India | | |
    3. 4.4.3.3 Japan | | |
    4. 4.4.3.4 South Korea | | |
    5. 4.4.3.5 Malaysia | | |
    6. 4.4.3.6 Thailand | | |
    7. 4.4.3.7 Indonesia | | |
    8. 4.4.3.8 Rest of APAC | |
  4. 4.4.4 South America | | |
    1. 4.4.4.1 Brazil | | |
    2. 4.4.4.2 Mexico | | |
    3. 4.4.4.3 Argentina | | |
    4. 4.4.4.4 Rest of South America | |
  5. 4.4.5 MEA | | |
    1. 4.4.5.1 GCC Countries | | |
    2. 4.4.5.2 South Africa | | |
    3. 4.4.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Roche (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Abbott (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Illumina (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 PerkinElmer (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 F. Hoffmann-La Roche (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Natera (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Hologic (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Genomic Health (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sequenom (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies | |
  10. 5.2.10 LabCorp (US) | | |
    1. 5.2.10.1 Financial Overview | | |
    2. 5.2.10.2 Products Offered | | |
    3. 5.2.10.3 Key Developments | | |
    4. 5.2.10.4 SWOT Analysis | | |
    5. 5.2.10.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TEST TYPE |
7. 6.4 US MARKET ANALYSIS BY DISEASE TYPE |
8. 6.5 US MARKET ANALYSIS BY TECHNOLOGY |
9. 6.6 CANADA MARKET ANALYSIS BY TEST TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY DISEASE TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY TECHNOLOGY |
12. 6.9 EUROPE MARKET ANALYSIS |
13. 6.10 GERMANY MARKET ANALYSIS BY TEST TYPE |
14. 6.11 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
15. 6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
16. 6.13 UK MARKET ANALYSIS BY TEST TYPE |
17. 6.14 UK MARKET ANALYSIS BY DISEASE TYPE |
18. 6.15 UK MARKET ANALYSIS BY TECHNOLOGY |
19. 6.16 FRANCE MARKET ANALYSIS BY TEST TYPE |
20. 6.17 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
21. 6.18 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
22. 6.19 RUSSIA MARKET ANALYSIS BY TEST TYPE |
23. 6.20 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
24. 6.21 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
25. 6.22 ITALY MARKET ANALYSIS BY TEST TYPE |
26. 6.23 ITALY MARKET ANALYSIS BY DISEASE TYPE |
27. 6.24 ITALY MARKET ANALYSIS BY TECHNOLOGY |
28. 6.25 SPAIN MARKET ANALYSIS BY TEST TYPE |
29. 6.26 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
30. 6.27 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
31. 6.28 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
32. 6.29 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
33. 6.30 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
34. 6.31 APAC MARKET ANALYSIS |
35. 6.32 CHINA MARKET ANALYSIS BY TEST TYPE |
36. 6.33 CHINA MARKET ANALYSIS BY DISEASE TYPE |
37. 6.34 CHINA MARKET ANALYSIS BY TECHNOLOGY |
38. 6.35 INDIA MARKET ANALYSIS BY TEST TYPE |
39. 6.36 INDIA MARKET ANALYSIS BY DISEASE TYPE |
40. 6.37 INDIA MARKET ANALYSIS BY TECHNOLOGY |
41. 6.38 JAPAN MARKET ANALYSIS BY TEST TYPE |
42. 6.39 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
43. 6.40 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
44. 6.41 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
45. 6.42 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
46. 6.43 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
47. 6.44 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
48. 6.45 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
49. 6.46 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
50. 6.47 THAILAND MARKET ANALYSIS BY TEST TYPE |
51. 6.48 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
52. 6.49 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
53. 6.50 INDONESIA MARKET ANALYSIS BY TEST TYPE |
54. 6.51 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
55. 6.52 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
56. 6.53 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
57. 6.54 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
58. 6.55 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
60. 6.57 BRAZIL MARKET ANALYSIS BY TEST TYPE |
61. 6.58 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
62. 6.59 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
63. 6.60 MEXICO MARKET ANALYSIS BY TEST TYPE |
64. 6.61 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
65. 6.62 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
66. 6.63 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
67. 6.64 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
68. 6.65 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
72. 6.69 MEA MARKET ANALYSIS |
73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
79. 6.76 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
80. 6.77 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
81. 6.78 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
83. 6.80 RESEARCH PROCESS OF MRFR |
84. 6.81 DRO ANALYSIS OF HEALTHCARE |
85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
88. 6.85 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
89. 6.86 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
90. 6.87 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
91. 6.88 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
92. 6.89 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
93. 6.90 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
95. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion) |
125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
126. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Prenatal Diagnostics Market Segmentation

Prenatal Diagnostics Market By Test Type (USD Billion, 2025-2035)

Non-Invasive Prenatal Testing (NIPT)
Chorionic Villus Sampling (CVS)
Amniocentesis
Ultrasound
Blood Tests

Prenatal Diagnostics Market By Disease Type (USD Billion, 2025-2035)

Chromosomal Abnormalities (e.g., Down Syndrome, Trisomy 18)
Neural Tube Defects (e.g., Spina Bifida, Anencephaly)
Genetic Disorders (e.g., Cystic Fibrosis, Sickle Cell Disease)
Heart Defects
Birth Defects

Prenatal Diagnostics Market By Prenatal Diagnostics Market (USD Billion, 2025-2035)

Next-Generation Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Microarrays
Karyotyping
Biochemical Markers

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”